Introduction
Metastatic prostate cancer (PCa) is characterized by movement of PCa cells out of the prostate gland into the circulation and subsequent trafficking to and colonization of distant tissues. Nearly 90% of all PCa metastases home to the bone marrow (BM), especially to spinal lumbar via the venous drainage system (Benjamin 2002) . The mechanism that directs such osteotropism is unclear and of profound importance for the development of antimetastatic therapeutics. Recent findings by our lab and others indicate that bone metastasis may be orchestrated by specific binding events between ligands displayed on the PCa cell surface and receptors expressed on BM endothelial cells (BMEC). In support, bone-metastatic PCa cells have been shown to attach more avidly to BMEC compared with endothelial linings from other organs, including umbilical vein (Lehr and Pienta 1998; Scott et al. 2001; Simpson et al. 2001) , lung (Scott et al. 2001) , aorta or skin (Cooper et al. 2000) . Consistent with these findings, we have reported previously that bone-metastatic prostate tumor MDA PCa 2b (MDA) cells (Navone et al. 1997 ) roll and form stable adhesive contacts under hydrodynamic shear flow on endothelial (E)-selectin expressed by BMEC (Dimitroff et al. 2004) . Rolling was supported principally by sialyl Lewis X (sLe X )-bearing glycoproteins, namely P-selectin glycoprotein ligand-1 (PSGL-1), displayed on the MDA cell surface. We hypothesize that recognition of BMEC by circulating PCa cells mimics and exploits identical E-selectin-E-selectin ligand interactions utilized by hematopoietic progenitor cells (HPC) in transit to BM (Hidalgo et al. 2002; Katayama et al. 2003) . That is, like bone-tropic HPC (Dimitroff et al. 2001) , MDA cells also express the sLe X -bearing glycoform of PSGL-1 (Dimitroff et al. 2005) . Further, the amount of PSGL-1 and sLe X on PCa tissue is associated with PCa grade or metastasis (Jorgensen et al. 1995; Martensson et al. 1995; Idikio 1997; Dimitroff et al. 2004 Dimitroff et al. , 2005 . Metastatic PCa cells express functional CXCR4 chemokine receptor (Taichman et al. 2002; Sun et al. 2003; Singh et al. 2004; Engl et al. 2006) , collagenases (Singh et al. 2004) , ADAM (a disintegrin and metalloproteinase) (Najy et al. 2008) , as well as several active integrin heterodimers (Cress et al. 1995; Fornaro et al. 2001; Cooper et al. 2002; Nemeth et al. 2003; Engl et al. 2006) . Taken together, these findings support a model whereby PCa cell metastasis to bone obeys the multistep paradigm of HPC recruitment to bone, defined as the "hematopoietic mimicry" hypothesis (Barthel et al. 2007) .
Based on the putative role of sLe X in PCa cell adhesion and metastasis, understanding how sLe X biosynthesis is regulated is an important yet underappreciated aspect of PCa pathobiology. In the case of HPC and leukocytes, synthesis of sLe
x on E-selectin-binding membrane proteins is well established; it is characterized by a series of catalytic steps in the Golgi compartment by members of the glycosyltransferase gene family α1,3 Fucosyltransferases are upregulated in E-selectin-binding PCa cells (Lowe 2002 (Lowe , 2003 Lowe and Marth 2003) . One of the major E-selectin-binding glycans is a sLe X moiety on "core 2" branched O-linked glycans. Synthesis of this determinant is initiated by core 2 branching enzymes, β1,6 Nacetylglucosaminyltransferases (C2GlcNAcT). The sialyllactosamine backbone is completed by sequential catalysis mediated by β1,4 galactosyl (GalT)-and α2,3 sialyltransferases (ST). The terminal step in sLe X synthesis on the core 2 glycan involves the transfer of fucose to N-acetylglucosamine by α1,3 fucosyltransferases (FT) (de Vries et al. 2001) . Of the six known α1,3 FTs encoded in the human genome, FT4 and FT7 are expressed in HPC, neutrophils, and T cells and represent key enzymes in selectin ligand-mediated trafficking during routine immunosurveillance and inflammatory conditions (Clarke and Watkins 1996; Knibbs et al. 1996 Knibbs et al. , 1998 Wagers et al. 1996; Le Marer et al. 1997; Naiyer et al. 1999; Huang et al. 2000; Weninger et al. 2000; Homeister et al. 2001; Smithson et al. 2001; Schottelius et al. 2003) . In addition, FT4 and FT7 as well as two other α1,3 FTs 3 and 6 are all associated with progression of at least one of several cancers, including leukemia (Le Marer et al. 1997; Kannagi 2001) , colon (Majuri et al. 1995; Weston et al. 1999; Hiller et al. 2000) , breast (Matsuura et al. 1998; Ding and Zheng 2004) , lung (Ogawa et al. 1996; Togayachi et al. 1999) , liver (Liu et al. 2000; Wang et al. 2003) , gastric (Petretti et al. 1999) , or pancreatic (Mas et al. 1998; Aubert et al. 2000) . That is, evidence suggests that these enzymes mediate sialyl Lewis carbohydrate synthesis, principally sLe X and/or sLe a , which may in turn trigger selectin-binding activity and promote tumor growth and metastasis (Barthel et al. 2007; Miyoshi et al. 2008) . In PCa, however, the role of glycosyltransferases, in particular α1,3 FTs, has been largely understudied.
In this report, we present genetic and immunochemical evidence implicating α1,3 FTs as key determinants in the biosynthesis of sLe X as well as in the generation of E-selectin-binding glycans on metastatic PCa cells. We observed a 31-and 10-fold enhancement in gene expression of FT3 and FT6, respectively, dated the conspicuous ESL activity of the bone-metastatic PCa cell line, MDA PCa 2b (MDA), which we will refer to henceforth as ESL + MDA cells (Dimitroff et al. 2005 ) ( Figure 1A ). In contrast, other metastatic PCa cell lines, including PC-3, PC-3M LN4, LNCaP, and DU-145, did not bind E-selectin as previously described (Dimitroff et al. 2005) (Figure 1A ). In control binding experiments, HPC (KG1a) cells also possessed robust ESL activity as reported previously (Dimitroff et al. 2001 (Dimitroff et al. , 2004 , while normal prostate epithelial cells did not. In experiments (not shown) neither normal prostate nor metastatic PCa cells, including MDA cells, bound P-selectin, in contrast to KG1a cells, which bound P-selectin avidly. Pretreating KG1a cells and MDA cells with neuraminidase ( Figure 1B) or EDTA (not shown) blocked E-selectin-binding completely. Removal of the surface protein by preincubation with bromelain blocked KG1a and MDA E-selectin-binding by 20% and 50%, respectively (not shown), indicating that glycoproteins terminated in sialic acid were major contributors of the E-selectin-binding phenotype ( Figure 1B ). Residual ESL activity on these cells was likely due to glycolipid ligands as previously described S R Barthel et al. (Dimitroff et al. 2005) . These results strengthen the hypothesis that bone-metastatic PCa cells mimic HPC cells in recognition of E-selectin through the upregulation and synthesis of sialic acid-bearing glycans. Sialic acid-bearing glycans are synthesized in HPCs by well-established biosynthetic pathways involving glycosyltransferases (Lowe 2002 (Lowe , 2003 Lowe and Marth 2003) . Thus, we first determined whether glycosyltransferases involved in generating E-selectin-binding determinants on HPC were also involved in the synthesis of ESL on MDA cells. Using real-time PCR and ESL + KG1a (HPC) cells as a positive control for FT4 and FT7 expression, we analyzed the expression of glycosyltransferase genes in ESL + MDA cells and in ESL − metastatic PCa cell lines PC-3, PC-3M LN4, LNCaP, and DU-145. As shown in Table I , we used primer sets specific for core 2 β1,6 N-acetylglucosaminyl-(C2GlcNAcT), β1,4 galactosyl-(GalT), α2,3 sialyl-(ST), and α1,3 FTs. RNA was purified from cells and reverse transcribed, and cDNA was used as a template for PCR in real-time. Expression of glycosyltransferase mRNA was normalized to GAPDH mRNA levels, compared with levels of mRNA in normal prostate tissue, and then expressed as mRNA fold difference. The mean (standard error of the mean, SEM) was calculated from a minimum of three separate experiments. Of note, we used normal prostate tissue and not normal human prostate epithelial cell cultures as a comparison tissue. Two of the major supplements in a human prostate epithelia growth medium are retinoic acid and hydrocortisone. Retinoic acid and hydrocortisone are potent negative and positive regulators, respectively, of glycosyltransferases involved in sLe X and ESL synthesis (Liepkalns et al. 1995; Biol-N'garagba et al. 2003; Yamanaka et al. 2008 ). Since we were interested in studying the role of glycosyltransferases in ESL expression in PCa, we considered that normal prostate tissue may express a more native and accurate glycosyltransferase expression pattern than expressed in cultured prostate epithelia. Thus, we avoided the down-or upregulation of glycosyltransferase levels that might be associated with normal prostate epithelia grown in culture and that could erroneously augment differences when comparing expression with metastatic PCa cells.
In control experiments, ESL + KG1a cells expressed a 54-and 88-fold elevation of FT4 and FT7, respectively, compared with normal prostate tissue (Figure 2 ). High expression of FT4 and FT7 is in agreement with a prior report establishing these two enzymes as key regulators in the synthesis of sialic acid-bearing glycans on KG1a cells (Clarke and Watkins 1997) of sialyllactosamine E-selectin-binding structures, including C2GlcNAcTI-III, β1,4 GalTI and III, and α2,3 STs, ST3GalI, III and IV. Likewise, all ESL − metastatic PCa cell lines expressed C2GlcNAcTs, GalTs, STs, as well as eight of nine FTs; however, none displayed elevated FT3 or FT6 (Figure 2 (Phillips et al. 1990; Iwai et al. 1993; Weitz-Schmidt et al. 1996; Inoue et al. 1997) , we assayed whether one or both of the sLe X or sLe a antigens may be responsible for the FT3-and FT6-mediated ESL activity on MDA cells. We performed flow cytometric analysis with several mAbs that recognize different structural variants of sLe X and also analyzed sLe a . Graphical representations of mAb specificities for Lewis carbohydrate epitopes are depicted in Figure 3 . In control experiments, ESL + KG1a cells reacted with all five anti-sLe X mAbs, including HECA-452, CSLEX-1, FH-6, KM-93, and CHO-131 ( Figure 4A ). Robust synthesis of sLe X in KG1a cells is consistent with the high expression of FT4 and FT7 in Figure 2 and in agreement with previous reports (Clarke and Watkins 1997; Dimitroff et al. 2001) . ESL + MDA cells also reacted with anti-sLe X mAbs, including HECA-452, CSLEX-1, FH-6, and KM-93. MDA cells, however, were not reactive to mAb CHO-131, an indicator of sLe X on core 2 O-glycans and a positive predictor of P-selectin-binding (Walcheck et al. 2002; Ni et al. 2006) (Figure 4A ). Lack of CHO-131 reactivity is, therefore, in accord with cell binding results in which MDA cells bound E-but not P-selectin. Furthermore, neither MDA nor KG1a cells expressed Le X or sLe a ( Figure 4B ). The absence of Le X expression on MDA cells is consistent with 49-and 68-fold decreases in FT4 and FT9 (Figure 2) , respectively, which fucosylate nonsialylated lactosamines (de Vries et al. 2001; Nakayama et al. 2001) , and is in agreement with previous reports of minimal Le X staining in formalin-fixed benign and PCa tissue (Martensson et al. 1995) . In contrast to MDA cells, HT-29 colon carcinoma cells were positive for Le X and for sLe a as reported previously (Mack et al. 1998; Hasegawa et al. 2005 (Martensson et al. 1995) . These results suggest that α1,3 FT activity, presumably contributed by FT3 and FT6, may control ESL activity on circulating PCa cells and that sLe a , though a critical carbohydrate feature of ESL on colorectal and pancreatic cancer cells (Iwai et al. 1993; Inoue et al. 1997; Yoshida et al. 1999 ) may not be a key Lewis carbohydrate structure for eliciting ESL activity on metastatic PCa cells.
Since sLe X was expressed on ESL + MDA cells, we assayed whether sLe X was also expressed on ESL − metastatic PCa PC-3 cells. There was minimal expression of sLe X on ESL − PC-3 cells as assayed with HECA-452, CSLEX-1, FH-6, KM-93, and CHO-131 ( Figure 4A ). Moreover, PC-3 cells expressed Le y , but not sLe a , Le X , or Le b ( Figure 4B ). Another ESL − cell line, LNCaP, also expressed only minimal sLe X , whereas PC-3M LN4 and DU-145 cell lines expressed a high amount based on HECA-452 mAb reactivity (data not shown). However, PC-3M LN4 and DU-145 cell lines do not contain anti-sLe X mAbreactive glycoproteins (Dimitroff et al. 2005 shaded histograms: staining with isotype control mAb. ESL + cells were recognized by anti-sLe X mAbs, HECA-452, CSLEX-1, FH-6, KM-93, whereas ESL − PC-3 cells were negative for sLe X . ESL + and ESL − PCa cells were negative for sLe a and positive for Le Y . These experiments were performed a minimum of three times.
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Expression of sLe and FT3, FT6, FT7, and FT9 corresponds Figures 1A and Figure 2) , we hypothesized that the ESL − activity might be the result of a decrease in native ESL expression, i.e., through prolonged culturing of PCa cells in vitro. In fact, we found that long-term culturing of MDA cells in the media recommended by the manufacturer led to reduced E-selectin-binding. Such loss of ESL activity might be due to diminution in α1,3 FT expression. We, therefore, took advantage of this drift in ESL phenotype and determined whether loss of E-selectin-binding was associated with a corresponding loss in expression of FT3 and FT6. As shown in photomicrographs, we created ESL hi and ESL lo MDA cell variants, based on ability to bind E-selectin (5A and B). Expression of sLe X was reduced on ESL lo MDA cells compared to ESL hi , indicating that the loss in ESL activity could be the result of diminished sLe X synthesis ( Figure 5C ). In Western blot assays probed with antisLe X mAb HECA-452, ESL hi MDA variants expressed sLe X on the 120 kDa membrane glycoprotein, identified previously as PSGL-1 (Dimitroff et al. 2005 ) ( Figure 5E ). In ligand blotting assays, PSGL-1, along with another glycoprotein, identified before as ESL-1 (Dimitroff et al. 2005) , bound E-selectin-Ig chimera ( Figure 5E ). These blots confirmed prior findings, indicating that PSGL-1 and not ESL-1 functions as the principal E-selectin glycoprotein ligand on MDA cells (Dimitroff et al. 2005) . On the other hand, ESL lo MDA cells neither expressed sLe X nor E-selectin-binding determinants on membrane glycoprotein ( Figure 5E ), consistent with their inability to recognize E-selectin in cell binding assays and with their reduced expression of sLe X ( Figure 5A , B, and C). Of note, flow cytometric analysis of PSGL-1 showed that both ESL lo and ESL hi MDA variants expressed a similar amount of PSGL-1 protein ( Figure  5D ). These results suggested that sLe X -synthesizing enzymes were upregulated in ESL hi compared with ESL lo MDA variants. To identify glycosyltransferases that directly relate to ESL activity on ESL hi MDA cells, we analyzed mRNA expression of C2GlcNAcTs, GalTs, STs, and FTs by real-time PCR. We found that ST3Gal-III and FT3, FT6, FT7, and FT9 were upregulated by 11-, 131-, 51-, 5-, and 61-fold, respectively, in ESL hi MDA cells compared with expression levels in ESL lo MDA cells (Figure 6 ). These data were consistent with the difference in the mRNA expression level between ESL + MDA and ESL − PCa cells (Figure 2 ) and reinforced the importance of FT3 and FT6, and potentially FT7, in creating sLe X and in generating the ESL activity of metastatic PCa cells. Indeed, transfection of FT3 into ESL − PC-3 cells, for example, induces sLe X expression and also enhances E-selectin-binding (Inaba et al. 2003) .
Discussion
In this study, we uncover a potential mechanistic role for glycosyltransferases, and in particular of α1,3 FTs, in the regulation and synthesis of sLe X on E-selectin-binding glycoproteins on metastatic PCa cells. The most prominent carbohydrate moiety implicated in PCa progression and metastasis is sLe X (Jorgensen et al. 1995; Idikio 1997; Dimitroff et al. 2004 Dimitroff et al. , 2005 . Elevation of sLe X expression indicates an alteration in glycosyltransferase activity in PCa cells. However, information Lysates from control ESL + HPC (KG1a) cells and ESL lo and ESL hi variants were subjected to SDS-PAGE on 4-20% reducing gels, transferred to immunoblot membrane, and blotted with anti-sLe X mAb HECA-452 or with E-selectin-Ig chimera. There were no glycoproteins bearing sLe X on ESL lo MDA cell variants, while sLe X and E-selectin-binding determinants were expressed by PSGL-1 on ESL hi MDA cell variants. Blotting with secondary rat IgM alone or with E-selectin-Ig in 5 mM EDTA did not result in any staining activity. These experiments were performed a minimum of five times.
on which glycosyltransferase(s) is responsible for the elevated synthesis of sLe X and resultant ESL activity on metastatic PCa cells has been heretofore unknown. Here, we implicate α1,3 FT3, FT6, and FT7 in the metastatic potential of PCa cells. Specifically, we show that FT3 and FT6 are upregulated 31-and 10-fold, respectively, in bone-metastatic MDA PCa Our findings, implicating that sLe X synthesis and ESL activity are regulated by FT3, FT6, and/or FT7 in metastatic PCa cells, are strikingly similar to the role of α1,3 FTs observed in several other cancers. In the case of carcinomas, elevation or involvement of FT3, FT6, and/or FT7 has been correlated with the progression of cancer of the colon (Majuri et al. 1995; Weston et al. 1999; Hiller et al. 2000) , breast (Matsuura et al. 1998; Ding and Zheng 2004) , lung (Ogawa et al. 1996) , liver (Liu et al. 2000; Wang et al. 2003) , and pancreas (Mas et al. 1998; Aubert et al. 2000) . Stable transfection of anti-sense sequences directed at FT3 into human colon carcinoma cells inhibits expression of sLe X or sLe a as well as blocks tumor cell adhesion, proliferation, and colonization of the liver (Weston et al. 1999; Hiller et al. 2000) . Transfection of FT7 in lung adenocarcinoma cells induces colonization of the lung (Martin-Satue et al. 1999) . Over-expression of FT3 in PCa as well as FT6 in breast cancer cells leads to synthesis of sLe X , enhanced adhesion, and tumor growth (Matsuura et al. 1998; Inaba et al. 2003) .
The causal relationship between specific FT expression and organ-specific metastasis may potentially explain the inherent differences in the pattern of PCa metastasis between human and mouse. For example, the genes encoding FT3, FT5, and FT6 are arranged as a gene cluster on the short arm of human chromosome 19 (McCurley et al. 1995) . This cluster is absent in mouse. That is, phylogenetic studies indicate that the gene duplication event leading to the emergence of the FT3-FT5-FT6 gene cluster occurred before the separation of man and chimpanzee 10 million years ago but after the mammalian radiation 80 million years ago as well as after the evolution of the mouse (Costache et al. 1997) . Interestingly, 90% of all metastatic PCa is found in the BM of humans but only very rarely are there bone metastases found in transgenic mouse models of PCa (Gingrich et al. 1996; Benjamin 2002) . In fact, these TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice exhibit PCa metastasis mostly to the lymph nodes and lung (Gingrich et al. 1996) . Thus, our results attributing a role for FT3 and FT6 specifically in the bone-homing behavior of PCa could potentially explain why PCa cells metastasize preferentially to bone in humans but only occasionally in mouse. Indeed, FT3 and FT6, as well as FT7, have all been implicated in the osteotropism of breast cancer metastasis (Matsuura et al. 1998; Ding and Zheng 2004) . In fact, FT6 and FT3 expression levels have been associated with amount of sLe X in breast cancer tissue (Matsuura et al. 1998 ). FT5 has not been detected in breast cancer tissue or in normal epithelial tissue of the kidney, lung, stomach, bladder, uterus, ovary, or salivary gland, mirroring our results for PCa cells and for normal prostate epithelial tissue Matsuura et al. 1998) . These findings implicate a critical role for FT3, FT6, and FT7 in the metastasis of PCa.
Additionally, that elevation in FT expression may underlie neoplastic progression of PCa raises the mechanistic question as to why FT3 and FT6 are elevated in PCa. In gastric cancer, for example, FT3 upregulation may be triggered through aberrant transcriptional control due to the hypomethylated state of its promoter (Serpa et al. 2006) . There are at least 13 putative sites in the FT3 promoter for binding of several different transcription factors, suggesting that FT3 may be particularly susceptible to upregulation (Dabrowska et al. 2005) . FT6, on the other hand, may be regulated posttranscriptionally through aberrant RNA processing, as two different FT6 transcript sizes 2.5 and 3.5 kb have been identified in kidney, liver, or colon . The primer set used in our assays anneals to the 5 -untranslated region and, therefore, recognizes both FT6 splice variants. It, therefore, remains to be determined whether only one and/or both of the two splice variants are expressed in PCa cells.
We speculate that upregulation of α1,3 FT3, FT6, and/or FT7 triggers sLe X synthesis and ESL activity on metastatic PCa cells. How ESL activity promotes PCa metastasis in vivo, however, is still undefined. Regulation of PCa metastasis is likely controlled by a number of factors inherent to a PCa cell and distinct from ESL activity, including steroid receptors, growth/ chemotactic factors, integrins, receptor/cytoplasmic kinases, S R Barthel et al.
and transcriptional activators. It is clear that host microenvironmental factors in the prostate gland and in distant tissues, notably bone, also facilitate metastasis, by nurturing PCa cell exiting from the primary tumor and homing and colonization in metastatic sites. In this regard, we and others have shown that BMEC provide a specific repertoire of adhesion molecules, including galectins and CD44, as well as E-selectin, that engage metastatic PCa cells and mediate heterotypic and homotypic binding interactions under static or hydrodynamic shear flow conditions (Clausse et al. 1999; Glinsky et al. 2003; Draffin et al. 2004 ). These carbohydrate-dependent adhesive processes are critical based on their putative role in initiating the extravasation of circulating PCa cells into tissues, including bone. This mechanism has been formally elucidated in the leukocyte homing paradigm, which has served as a roadmap for our investigations on how PCa cells adhere to BMEC in blood flow. Our findings presented here and previously indicate that rolling of bone-metastatic MDA PCa cells on BMEC mimics HPC rolling behavior on BMEC via E-selectin -sLe X -bearing glycoconjugates (Dimitroff et al. 2004 (Dimitroff et al. , 2005 . PSGL-1 on MDA cells, in contrast to HPC, did not confer P-selectin ligand activity or express sLe X -core 2 O-glycans recognized by mAb CHO-131. In addition, ESL + MDA cells did not synthesize sLe a despite the upregulation of FT3. An obvious question then is whether metastatic PCa cells in vivo are also devoid of sLe a synthesis and unable to recognize P-selectin or whether circulating PCa cells acquire this capacity, i.e., through induction of O-linked core 2 glycans and sulfation of tyrosine residues on PSGL-1. In any case, our results suggest that loss of glycosyltransferase gene expression in metastatic PCa cells through continuous passaging in vitro may bias studies, and, therefore, strongly underrepresent the native role of selectin/selectin ligands in PCa progression and metastasis. In closing, identifying and understanding how sLe X and ESL are synthesized in metastatic PCa cell lines as well as in tumor tissue in vivo could be invaluable in providing mechanistic insight into how PCa cell extravasation through BMEC is regulated.
Materials and methods

Cell lines and tissues
Culture conditions for human metastatic prostate tumor cell lines, MDA PCa 2b, PC-3, PC-3M LN4 derived from bone metastases, LNCaP from a lymph node metastasis, and DU-145 from a brain metastasis (American Type Culture Collection (ATCC); Manassas, VA) have been described previously (Dimitroff et al. 2005) . Normal prostate epithelial cells were grown in a prostate epithelial basal medium as suggested by the manufacturer (Lonza, Inc., Walkersville, MD). Human HPC KG1a cell line (ATCC), expressing all glycosyltransferases necessary for ESL synthesis, was maintained as described previously (Dimitroff et al. 2005 City, CA) . Anti-PSGL-1 (CD162) mAb PL2 was from Fisher-Scientific (Suwanee, GA). Anti-β-actin mAb AC-15 was from Novus Biologicals (Littleton, CO). The following mAbs purchased from BD Biosciences were used as isotype controls: mouse IgG1; rat IgM; and mouse IgM. Secondary mAbs used in flow cytometric analyses purchased from BD Biosciences included: APC-conjugated goat anti-mouse IgG; FITCconjugated mouse anti-rat IgM; and FITC-conjugated rat antimouse IgM. FITC-conjugated goat anti-mouse IgG was from SouthernBiotech (Birmingham, AL). Secondary mAbs used in Western blotting were alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG and AP-conjugated rabbit anti-rat IgM (Zymed Laboratories, San Francisco, CA).
Real-time PCR analysis of glycosyltransferase gene expression
Cells/tissues were lysed in 1 mL Trizol R reagent (Invitrogen, Carlsbad, CA). Chloroform (0.2 mL) was added; tubes were capped and shaken vigorously for 15 s, incubated at 22
• C for 3 min, and then centrifuged at 12,000 RPM for 15 min at 4
• C. The upper, colorless phase was transferred to a clean eppendorf tube, mixed with 0.5 mL isopropanol, incubated at 22
• C for 10 min, and then centrifuged at 12,000 RPM for 15 min at 4
• C. The supernatant was aspirated, the RNA pellet rinsed with 1 mL of 75% ethanol in DEPC-treated water (Invitrogen), vortexed, centrifuged at 7500 RPM for 5 min at 4
• C, resuspended in 50 µL DEPC-treated water, and then incubated for 10 min at 37
• C to dissolve fully the RNA pellet. Genomic DNA contamination was removed from the preparation of total RNA with the RNeasy R Mini Kit, which included a DNAse I treatment step as per manufacturer's instructions (Qiagen, Valencia, CA). First-strand cDNA was synthesized from 0.5 µg total RNA using the iScript TM cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the following conditions: 5 min at room temperature, 30 min at 42
• C, and 5 min at 85
• C. Quantitation of human glycosyltransferase transcript expression by real-time PCR was performed on the iCycler iQ multicolor real-time PCR detection system (Bio-Rad) with iQ TM SYBR R Green Supermix (Bio-Rad) using 1 µL cDNA. The PCR conditions included 1 cycle at 95
• C for 2 min followed by 45 cycles at 95
• C for 15 s, 60
• C for 15 s, and 72
• C for 45 s. The amount of glycosyltransferase transcript was normalized to the amount of GAPDH transcript in the same cDNA sample. Relative fold differences in transcript expression were approximated using the Comparative C T method. Product specificity was verified by melt curve analysis according to the following conditions: 1 cycle at 95
• C for 1 min, 1 cycle at 55
• C for 1 min, and 80 cycles of 0.5 • C incremental increases each of 10 s beginning at 55
• C. The absence of genomic DNA contamination was confirmed by performing real-time α1,3 Fucosyltransferases are upregulated in E-selectin-binding PCa cells PCR with 1 µL of RNA that had not been subjected to reverse transcription. Primer sequences used for expression analysis of glycosyltransferases as well as of GAPDH by real-time PCR are shown in Table I .
Flow cytometry
Cells from suspension cultures or from adherent prostate tumor cell cultures were harvested by 1 mM EDTA, washed, and suspended at 1-5 × 10 5 cells in 100 µL cold PBS/2% FBS. The mAbs recognizing Lewis carbohydrate antigens along with appropriate isotype-matched control mAbs (2 µg/test) were incubated with cells for 30-60 min at 4
• C. Following one wash in PBS/2% FBS, cells were incubated with either FITC-or APCconjugated secondary mAb for 30 min at 4
• C. After secondary mAb incubation, cells were pelleted, washed, and resuspended in 500 µL PBS. Fluorescence measurements were collected within 1 h on a BD FACSCanto TM apparatus (BD Biosciences). Data were analyzed using the FlowJo software (Tree Star, Inc., Ashland, OR). Cells were gated based on forward and side scatter.
Selectin-binding assay
To examine E-and P-selectin-binding of metastatic PCa cells, we developed a cell adhesion assay using polystyrene 96-well tissue culture plates with black sides and clear bottoms (Corning, Acton, MA). This system allowed for qualitative and quantitative analysis of limited numbers of PCa cells. Wells were coated first in triplicate with 10 µg/mL recombinant human Eor P-selectin-Ig (R&D Systems, Minneapolis, MN) or negative control human IgG for 24 h at 4
• C. Wells were incubated with 1% BSA/PBS for 15 min at 4
• C to block nonspecific cell binding. Cells were prepared for adhesion by fluorescent labeling with 5 µg/mL calcein AM (Molecular Probes, Invitrogen) in adhesion assay buffer (RPMI 1640/0.2% BSA) for 30 min at 22
• C. Cells were added to wells in 100 µL of 1 × 10 5 cells per well and incubated for 1 h at 4
• C. Wells were washed three times with PBS. Fluorescence (485 nm excitation; 535 nm emission) was measured on a Wallac Victor 2 plate reader (Perkin Elmer, Waltham MA) at 0.1 s intervals at the Institute of Chemistry and Cell Biology Screening Facility of Harvard Medical School (Boston, MA). Values represent cell binding as a percentage of total input cells.
Western blot analysis
Western blotting was performed as described previously (Dimitroff et al. 2004 (Dimitroff et al. , 2005 . Briefly, total protein from HPC KG1a cells or membrane protein from MDA cells was solubilized in a protease inhibitor buffer containing 2% NP-40, and the concentration was determined by Bradford method (Dimitroff et al. 2001) . Solubilized protein was diluted in a reducing sample buffer and separated on 4-20% Criterion TM SDS-PAGE gradient gels (Bio-Rad). Resolved proteins were immunoblotted onto Criterion Gel TM polyvinylidene difluoride membranes (Bio-Rad), blocked in FBS for 1 h at 22
• C, and then incubated with HECA-452 mAb anti-sLe X (1 µg/mL), isotype control rat IgM, mouse E-selectin-Ig chimera (1 µg/mL) (R&D Systems), isotype control human IgG (1 µg/mL), or mouse IgG anti-β-actin (1 µg/mL) for 1 h at 37
• C. Blots were then washed three times with Tris-buffered saline and 0.1% Tween-20, incubated with alkaline phosphatase (AP)-conjugated rabbit anti-rat IgM, AP-anti-human IgG, or AP-anti-mouse IgG (all at 1:1000; Zymed Laboratories, Inc., San Francisco, CA) for 1 h at 22
• C, and washed three times for 15 min each with Tris-buffered saline and 0.1% Tween-20. Blots were developed with a Western Blue R AP substrate (Promega, Madison, WI).
Enzymatic and inhibitor treatments
Where indicated, cells were pretreated in an adhesion assay buffer with 10 mM EDTA or with 0.2 U/mL Vibrio cholerae neuraminidase (sialidase) (Roche Applied Sciences, Indianapolis, IN), an enzyme that cleaves terminal sialic acid residues and abrogates selectin/selectin ligand binding, for 1 h at 37
• C. Alternatively, cells in an adhesion assay buffer were pretreated for 1 h at 37
• C with 0.1% bromelain (Sigma), a protease with broad peptide specificity.
Statistical analysis
Results were analyzed by one-way ANOVA with Dunnett's posttest on GraphPad Prism software R (San Diego, CA). 
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